| 10.49 0.3 (2.94%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.99 | 1-year : | 15.17 |
| Resists | First : | 11.12 | Second : | 12.98 |
| Pivot price | 9.64  |
|||
| Supports | First : | 8.1 | Second : | 6.73 |
| MAs | MA(5) : | 10.06  |
MA(20) : | 10.13 |
| MA(100) : | 7.37 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 60.8 |
D(3) : | 52.6 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 25 | Low : | 3.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NTHI ] has closed below upper band by 23.2%. Bollinger Bands are 9.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.51 - 10.55 | 10.55 - 10.58 |
| Low: | 9.96 - 10 | 10 - 10.04 |
| Close: | 10.42 - 10.49 | 10.49 - 10.55 |
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Tue, 04 Nov 2025
NeOnc Technologies appoints Amir Heshmatpour as CEO - Investing.com
Tue, 04 Nov 2025
NeOnc Technologies Appoints Amir Heshmatpour as Chief - GlobeNewswire
Tue, 04 Nov 2025
NeOnc (NASDAQ: NTHI) names Amir Heshmatpour CEO; Dr. Chen to focus on CMO/CSO - Stock Titan
Thu, 30 Oct 2025
NeOnc Technologies Appoints New Executive Chairman - TipRanks
Tue, 28 Oct 2025
NeOnc (NTHI) names H.H. Sheikh Nahyan NuroMENA chair, forging UAE–US brain cancer ties - Stock Titan
Thu, 09 Oct 2025
NeOnc Technologies: From Survival Mode To Expansion Mode (NTHI) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 7.94e+006 (%) |
| Held by Institutions | 52.6 (%) |
| Shares Short | 93 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -69 % |
| Return on Assets (ttm) | 809.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 59990 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 137750 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|